FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964411946> ?p ?o ?g. }

• W1964411946 endingPage "1078" @default.
• W1964411946 startingPage "1066" @default.
• W1964411946 abstract "HepatologyVolume 11, Issue 6 p. 1066-1078 Special ArticleFree Access Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension Professor JÜRg Reichen M.D, Corresponding Author Professor JÜRg Reichen M.D Department of Clinical Pharmacology, University of Berne, Switzerland was the recipient of a Research Career Development Award from the Swiss Nationl Foundation for Scientific Research (No. 3. 731.0.87).Department of Clinical Pharmacology, University of Berne, Murtenstrasse 35, 3010-Berne, Switzerland===Search for more papers by this author Professor JÜRg Reichen M.D, Corresponding Author Professor JÜRg Reichen M.D Department of Clinical Pharmacology, University of Berne, Switzerland was the recipient of a Research Career Development Award from the Swiss Nationl Foundation for Scientific Research (No. 3. 731.0.87).Department of Clinical Pharmacology, University of Berne, Murtenstrasse 35, 3010-Berne, Switzerland===Search for more papers by this author First published: June 1990 https://doi.org/10.1002/hep.1840110625Citations: 60 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981; 305: 1371– 1374. 2 Reynolds TB. Promises! promises! hemodynamics and portosystemic shunts. N Engl J Med 1974; 290: 1484– 1485. 3 Reichen J, Lebrec D. The effect of drugs on the portal circulation. J Hepatol 1987; 5: 235– 240. 4 Groszman RJ. Reassessing portal venous pressure measurements. Gastroenterology 1984; 86: 1611– 1614. 5 Groszman RJ. The measurement of liver blood flow using clearance techniques. HEPATOLOGY 1983; 3: 1039– 1040. 6 Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of hemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5: 144– 148. 7 Gines P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballeria J, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987; 7: 122– 128. 8 Van Leeuwen DJ, Sherlock S, Scheuer PJ, Dick R. Wedged hepatic venous pressure recording and venography for the assessment of pre-cirrhotic and cirrhotic liver disease. Scand J Gastroenterol 1989; 24: 65– 73. 9 Vinel JP, Cassigneul J, Levade M, Voigt JJ, Pascal JP. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. HEPATOLOGY 1986; 6: 116– 117. 10 Startiz M, Poralla T, Meyer zum Büschenfelde K-H. Intravascular oesophageal variceal pressure (IOVP) assessed by endoscopic fine needle puncture under basal conditions, Valsalva's manoeuvre, and after glyceryl trinitrate application. Gut 1985; 26: 525– 530. 11 Gertsch P, Meister JJ. Pressure measurements in oesophageal varices: preliminary report on a new non-invasive method. Gut 1987; 28: 1162– 1165. 12 Bosch J, Bordas JM, Rigau J, Viola C, Mastai R, Kravetz D, Navasa M, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. HEPATOLOGY 1986; 6: 667– 672. 13 Burns P, Taylor K, Blei AT. Doppler flowmentry and portal hypertension. Gastroenterology 1987; 92: 824– 826. 14 Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982; 83: 1090– 1096. 15 Zeeh J, Lange H, Bosch J, Pohl S, Loesgen H, Eggers R, Navasa M, et al. Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 1988; 95: 749– 759. 16 The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988; 319: 983– 989. 17 Bosch J, Maistai R, Kravetz D, Bruix J, Rigau J, Rodés J. Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis: clinical and haemodynamic correlations in 100 patients. J Hepatol 1985; 1: 125– 139. 18 Cales P, Braillon A, Jiron MI, Lebrec D. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis: lack of correlation with esophageal varices and gastrointestinal bleeding: effect of propranolol. J Hepatol 1984; 1: 37– 46. 19 Whipple AO. The problem of portal hypertension in relation to the hepatosplenopathies. Ann Surg 1945; 122: 449– 75. 20 Shibayama Y, Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. HEPATOLOGY 1985; 5: 643– 648. 21 Reichen J. Etiology and pathophysiology of portal hypertension. Z Gastroenterol 1988; 26: 3– 7. 22 Blendis LM, Orrego H, Crossley IR, Blake JE, Medline A, Israel Y. The role of hepatocyte enlargement in hepatic pressure in cirrhotic and noncirrhotic alcoholic liver disease. HEPATOLOGY 1982; 2: 539– 546. 23 Orrego H, Blendis IM, Crossley IRE. Correlation of intrahepatic pressure with collagen in the Disse space in humans and in the rat. Gastroenterology 1981; 80: 546– 556. 24 Vidins EI, Britton RS, Medline A, Blendis LM, Israel Y, Orrego H. Sinusoidal caliber in alcoholic and nonalcoholic liver disease: diagnostic and pathogenic implications. HEPATOLOGY 1985; 5: 408– 414. 25 Shibayama Y, Nakata K. The role of sinusoidal stenoses in portal hypertension of liver cirrhosis. J Hepatol 1989; 8: 60– 66. 26 Pesce C, Colacino R. The sinusoids in cirrhosis: a morphometric study. Virchow's Arch [A] 1986; 410: 217– 219. 27 Krogsgaard K, Gluud C, Henriksen JH, Christoffersen P. Correlation between liver morphology and portal pressure in alcoholic liver disease. HEPATOLOGY 1984; 4: 699– 703. 28 Fenyves D, Pomier-Layrargues G, Willems B, Cole J. Intrahepatic pressure measurement: not an accurate reflection of portal vein pressure. HEPATOLOGY 1988; 8: 211– 216. 29 Hadjis NS, Blumgart LH. Role of liver atrophy, hepatic resection and hepatocyte hyperplasia in the development of portal hypertension in biliary disease. Gut 1987; 28: 1022– 1028. 30 Reichen J, Egger B, Ohara N, Zeltner TB, Zysset T, Zimmermann A. Determinants of hepatic functions in liver cirrhosis in the rat: a multivariate analysis. J Clin Invest 1988; 82: 2069– 2076. 31 Richardson PDI, Withrington PG. Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology 1981; 81: 159– 173. 32 Richardson PDI, Withrington PG. Liver blood flow. II. effects of drugs and hormones on liver blood flow. Gastroenterology 1981; 81: 356– 375. 33 Tran-Thi TA, Gyufko K, Häussinger D, Decker K. Net prostaglandin release by perfused rat liver after stimulation with phorbol 12-myristate 13-acetate. J Hepatol 1988; 6: 151– 157. 34 Bardadin KA, Desmet VJ. Ultrastructural observations on sinusoidal endothelial cells in chronic active hepatitis. Histopathology 1985; 9: 171– 181. 35 Altin JG, Bygrave FL. Non-parenchymal cells as mediators of physiological response in liver. Mol Cell Biochem 1988; 83: 3– 4. 36 Lapointe DS, Olson MS. Alteration of hepatic tissue spaces by platelet-activating factor and phenylephrine. HEPATOLOGY 1989; 9: 278– 284. 37 Villamediana LM, Sanz E, Fernandez-Gallardo S, Caramelo C, Sanchez M, Braquet P, Lopez-Novoa JM. Effects of the plateletactivating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. Life Sci 1986; 39: 201– 205. 38 Ballardini G, Fallani M, Biagini G, Bianchi FB, Pisi E. Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchow's Arch [B] 1988; 56: 45– 49. 39 Yokoi Y, Namihisa T, Matsuzaki K, Miyazaki A, Yamaguchi Y. Distribution of Ito cells in experimental hepatic fibrosis. Liver 1988; 8: 48– 52. 40 Minato Y, Hasumura Y, Takeuchi J. The role of fat-storing cells in Disse space fibrogenesis in alcoholic liver disease. HEPATOLOGY 1983; 3: 559– 566. 41 Henriksen JH, Lassen NA. Pressure profile in liver sinusoids. Liver 1988; 8: 88– 94. 42 Rappaport AM, MacPhee PJ, Fisher MM, Phillips MJ. The scarring of the liver acini (cirrhosis): tridimensional and microcirculatory considerations. Virchow's Arch [A] 1983; 402: 107– 137. 43 MacPhee PJ, Schmidt EE, Keown PA, Groom AC. Microcirculatory changes in livers of mice infected with murine hepatitis virus: evidence from microcorrosion casts and measurements of red cell velocity. Microvasc Res 1988; 36: 140– 149. 44 Horn T, Christoffersen P, Henriksen JH. Alcoholic liver injury: defenestration in noncirrhotic livers-a scanning electron microscopic study. HEPATOLOGY 1987; 7: 77– 82. 45 MacPhee PJ, Dindzans VJ, Fung LS, Levy GA. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. HEPATOLOGY 1985; 5: 649– 660. 46 Cohn JN, Khatri IM, Groszman RJ, Kotelanski B. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique. Am J Med 1972; 53: 704– 714. 47 Vorobioff J, Bredfeldt JE, Groszman RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244 (1): G52– G57. 48 Benoit JN, Wocmack WA, Hernandez L, Granger DN. “Forward” and “backward” flow mechanisms of portal hypertension. Gastroenterology 1985; 89: 1096– 1099. 49 Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989; 151: 530– 535. 50 Siegel JH, Goldwyn RM, Farrell J. Hyperdynamic states and the physiologic determinants of survival. Arch Surg 1974; 108: 283– 292. 51 Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P, Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27: 1204– 1209. 52 Benoit JN, Womack WA, Korthuis RJ, Wilborn WH, Granger DN. Chronic portal hypertension: effects on gastrointestinal blood flow distribution. Am J Physiol 1986; 250 (4 Pt 1): G535– G539. 53 Keller U, Gerber PP, Buehler FR, Stauffacher W. Role of the splanchnic bed in extracting circulating adrenaline and noradrenaline in normal subjects and in patients with cirrhosis of the liver. Clin Sci 1984; 67: 45– 49. 54 Henriksen JH, Ring-Larsen H, Christensen NJ. Circulating noradrenaline and central hemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985; 20: 1185– 1190. 55 Willet IR, Esler M, Jennings G, Dudley FJ. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. Lancet 1986; 2: 939– 943. 56 Vorobioff J, Garcia-Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, Hernandez-Ortiz J. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. HEPATOLOGY 1989; 9: 88– 91. 57 Hadengue A, Lee SS, Moreau R, Braillon A, Lebrec D. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. HEPATOLOGY 1987; 7: 644– 647. 58 Cummings SA, Groszman R, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserininduced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986; 89: 501– 513. 59 Lee SS, Moreau R, Hadengue A, Cerini R, Koshy A, Lebrec D. Glucagon selectively increases splanchnic blood flow in patients with well-compensated cirrhosis. HEPATOLOGY 1988; 8: 1501– 1505. 60 Benoit JN, Zimmermann B, Premen AJ, Go VLW, Granger DN. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 251 (5 Pt 1): G674– G677. 61 Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430– 435. 62 Hashizume M, Inokuchi K, Tanaka K. The role of prostacyclin in patients with portal hypertension. Liver 1985; 5: 89– 93. 63 Krell H, Dietze E. Hemodynamic and metabolic responses to leukotriene C4 in isolated perfused rat liver. HEPATOLOGY 1989; 10: 300– 305. 64 Unger LS, Reilly FD. Hepatic microvascular regulatory mechanisms. VII. Effects of endoportally infused endotoxin on microcirculation and mast cells in rats. Microcirc Endothelium Lymphatics 1986; 1: 47– 74. 65 Minuk GY, MacCannell KL. Is the hypotension of cirrhosis a GABA-mediated process?. HEPATOLOGY 1988; 8: 73– 77. 66 Martini GA, Arndt H, Baltzer G. Pulmonary circulation in portal hypertension. Ann NY Acad Sci 1970; 170: 280– 295. 67 Hunt S, Vaamonde C, Ratassi T. Circulating levels of vasoactive polypeptide in liver disease. Arch Intern Med 1979; 139: 994– 996. 68 Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239– 242. 69 Huet PM, Goresky CA, Villeneuve JP, Marleau D, Lough JO. Assessment of liver microcirculation in human cirrhosis. J Clin Invest 1982; 70: 1234– 1244. 70 Varin F, Huet P-M. Hepatic microcirculation in the pefused cirrhotic rat liver. J Clin Invest 1985; 76: 1904– 1912. 71 Reichen J, Le M. Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 1986; 78: 448– 455. 72 Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCushkey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. HEPATOLOGY 1985; 5: 683– 692. 73 Steffan AM, Gendrault JL, Kirn A. Increase in the number of fenestrae in mouse endothelial liver cells by altering the cytoskeleton with cytochalasin B. HEPATOLOGY 1987; 7: 1230– 1238. 74 Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325– 337. 75 Reichen J, Hirlinger A, Ha HR, Saegesser H. Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis. J Hepatol 1986; 3: 49– 58. 76 Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. HEPATOLOGY 1987; 7: 149– 154. 77 Schlichting P, Christensen E, Fauerholdt L, Poulsen H, Juhl E, Tygstrup N. Main causes of death in cirrhosis. Scand J Gastroenterol 1983; 18: 881– 888. 78 D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468– 475. 79 Conn HO. A peek at the Child-Turcotte classification. HEPATOLOGY 1981; 1: 673– 676. 80 Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. HEPATOLOGY 1987; 7: 660– 664. 81 Christensen E, Schlichting P, Andersen PK, Fauerholdt L, Schou G, Pedersen BV, Jahl E, et al. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables. Scand J Gastroenterol 1986; 21: 163– 174. 82 Neuberger J, Altman DG, Christensen E, Tygstrup N, Williams R. Use of a prognostic index in evaluation of liver transplatation for primary biliary cirrhosis. Transplantation 1986; 41: 713– 716. 83 Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. HEPATOLOGY 1983; 3: 896– 905. 84 Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. HEPATOLOGY 1989; 10: 1– 7. 85 Tygstrup N. Determination of hepatic galactose elimination capacity after a single intravenous injection in man. Acta Physiol Scand 1963; 58: 162– 172. 86 Bircher J, Kuepfer A, Gikalov I, Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976; 20: 484– 492. 87 Berry W, Reichen J. Bile acid metabolism: its relation to clinical disease. Semin Liver Dis 1983; 3: 330– 340. 88 Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976; 17: 959– 964. 89 Cotting J, Widmer T, Bircher J, Preisig R, Reichen J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis [Abstract]. HEPATOLOGY 1987; 7: 1119. 90 Schneider JF, Baker AL, Haines NM, Hatfield G, Boyer JL. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980; 79: 1145– 1150. 91 Henry DA, Kitchingman G, Langman MJ. 14C-Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 1985; 30: 813– 818. 92 Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller D. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. HEPATOLOGY 1982; 2: 317– 322. 93 Lashner BA, Jonas RB, Tang HS, Evans AA, Ozeran SE, Baker AL. Chronic hepatitis: disease factors at diagnosis predictive of mortality. Am J Med 1988; 85: 609– 614. 94 Gill RA, Goodman MW, Golfus GR, Onstad GR, Bubrick MP. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 1983; 198: 701– 704. 95 Saunders JB, Wright N, Lewis KO. Predicting outcome of paracetamol poisoning by using [14C]-aminopyrine breath test. Br Med J 1980; 2: 279– 280. 96 Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breat test in cirrhotic patients. HEPATOLOGY 1986; 6: 928– 931. 97 Hartmann AH, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24: 269– 276. 98 Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, Makino I. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 1984; 86: 514– 520. 99 Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T, Paumgartner G. Prognostic significance of serum bile acids in cirrhosis. HEPATOLOGY 1986; 6: 50– 53. 100 Islam S, Poupon RE, Barbare JC, Chretien Y, Darnis F, Poupon R. Fasting serum bile acid level in cirrhosis: a semi-quantitative index of hepatic function. J. Hepatol 1985; 1: 609– 617. 101 Merkel C, Bolognesi M, Finucci GF, Angeli P, Caregaro L, Rondana M, Gatta A. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989; 9: 16– 22. 102 Matsumata T, Kanematsu T, Yoshida Y, Furuta T, Yanaga K, Sugimachi K. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg 1987; 11: 678– 681. 103 Barbare JC, Poupon RE, Jaillon P, Prod'homme S, Darnis F, Poupon RY. Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis. J Hepatol 1985; 1: 253– 259. 104 Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis. Acta Med Scand 1982; 211: 303– 308. 105 Reichen J, Arts B, Schafroth U, Zimmermann A, Zeltner TB, Zysset T. Aminopyrine N-demethylation by rats with liver cirrhosis: evidence for the intact cell hypothesis: a morphometricfunctional study. Gastroenterology 1987; 93: 719– 726. 106 Gross JB, Reichen J, Zeltner T, Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of cirrhosis. HEPATOLOGY 1987; 7: 457– 463. 107 Williams SJ, Farrell GC. Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. HEPATOLOGY 1989; 10: 192– 197. 108 Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid therapy on nutrition and liver function in patients with cystic fibrosis and long-standing cholestasis. Gut 1990; (in press). 109 Conn HO. Vasopressin and nitroglycerin in the treatment of bleeding varices: the bottom line. HEPATOLOGY 1986; 6: 523– 525. 110 Ohara N, Reichen J. Pharmacological therapy of portal hypertension. Dig Dis 1986; 4: 208– 219. 111 Gimson AE, Westaby D, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. HEPATOLOGY 1986; 6: 410– 413. 112 Tsai YT, Lay CS, Lai KH, Ng NW, Yeh YS, Wang JY, Chiang TT, et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. HEPATOLOGY 1986; 6: 406– 409. 113 Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. HEPATOLOGY 1986; 6: 112– 115. 114 Freeman JG, Lishman AJ, Cobden I, Record CO. Terlipressin (Glypressin) versus vasopressin in the early treatment of esophageal varices. Lancet 1982; 2: 66– 68. 115 Vosnik J, Jedlicka K, Mulder JL, Cort JH. Action of the triglycyl hormonogen of vasopressin (glypressin) in patients with liver cirrhosis and bleeding esophageal varices. Gastroenterology 1977; 72: 605– 609. 116 Kravetz D, Bosch J, Terés J, Bruix J, Rimola A, Rodés J. Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. HEPATOLOGY 1984; 4: 442– 446. 117 Jenkins SA, Baxter JN, Corbett W, Devitt P, Ware J, Shields R. A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal hemorrhage. Br Med J 1985; 290: 275– 278. 118 Wahren J, Eriksson LS. The influence of a long-acting somatostatin analogue on splanchnic hemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol 1986; 21 (suppl 119): 103– 108. 119 Korthuis RJ, Benoit JN, Kvietys PR, Townsley MI, Taylor AE, Granger N. Humoral factors may mediate increased rat hindquarter blood flow in portal hypertension. Am J Physiol 1985; 249 (4 Pt 2): H827– H833. 120 Sikuler E, Groszman RJ. Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to systemic glucagon levels. HEPATOLOGY 1986; 6: 414– 418. 121 Bosch J, Kravetz D, Rodés J. Effects of somatostatin in hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 518– 525. 122 Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988; 94: 703– 708. 123 Ranek L, Vilstrup H, Iversen J, Petersen P, Milandri M. The effect of continuous vasopressin infusion on splanchnic blood flow, liver functin, and portal and central venous pressures in patients with cirrhosis. Scand J Clin Lab Invest 1984; 44: 251– 256. 124 Barbare JC, Poupon R, Jaillon P, Bories P, Aussanaire M, Darnis F, Michel H, et al. The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin and somatostatin. HEPATOLOGY 1984; 4: 59– 62. 125 Merkel C, Gatta A, Caregaro L, Sacerdoti D, Rondana M, Ruol A. Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis. Scand J Clin Lab Invest 1987; 47: 667– 672. 126 Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987; 22: 919– 925. 127 Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988; 6: 350– 358. 128 Gerbes AL, Remien J, Juengst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409– 1411. 129 Kiel JW, Pitts V, Benoit JN, Granger ND, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985; 248 (2 Pt 1): G192– G195. 130 Bomzon A, Blendis LM. Vascular reactivity in experimental portal hypertension. Am J Physiol 1987; 252 (2 Pt 1): G158– G162. 131 Ramond MJ, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol 1986; 21: 191– 196. 132 Lunzer MR, Manghani KK, Newman SP, Sherlock SP, Bernard AG, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975; 2: 382– 385. 133 Villamediana LM, Dieguez G, Santos JC, Garcia-Villalon AL, Caramelo C, Lopez-Novoa JM. Vascular reactivity to norepinephrine in rats with cirrhosis of the liver. Can J Physiol Pharmacol 1988; 66: 567– 572. 134 Reichen J, Saegesser H, Stuber R, Zysset T. Resistance of cirrhotic rat liver to the microvascular and functional effects of norepinephrine: down-regulation of hepatic adrenoreceptors [Abstract]?. HEPATOLOGY 1987; 7: 1032. 135 Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents: a study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988; 244: 283– 289. 136 Valla D, Graudin C, Geoffroy P, Braillon A, Lee SS, Lebrec D. Reversal of adrenaline-induced increase in azygos blood flow in patients with cirrhosis receiving propranolol. J Hepatol 1987; 4: 86– 92. 137 Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, Rodés J. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4: 71– 79. 138 Braillon A, Jiron MI, Valla D, Cales P, Lebrec D. Effect of propranolol on hepatic blood flow in patients with cirrhosis. Clin Pharmacol Ther 1985; 37: 376– 380. 139 Pagliaro L, Burroughs AK, Sorensen TIA, Lebrec D, Morabito A, D'Amico G, Tine F. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2: 71– 84. 140 Hosking SW, Kennedy HJ, Seddon I, Triger DR. The role of propranolol in congestive gastropathy of portal hypertension. HEPATOLOGY 1987; 7: 437– 441. 141 Burroughs AK, Jenkins WJ, Sherlock S, Denk A, Walt P, Osnafour TOK, Mackie S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539– 1542. 142 Silvain C, Chauvin C, Verneau A, Carretier M, Beauchant M. How many cirrhotics may receive proprano" @default.
• W1964411946 created "2016-06-24" @default.
• W1964411946 creator A5060207605 @default.
• W1964411946 date "1990-06-01" @default.
• W1964411946 modified "2023-09-23" @default.
• W1964411946 title "Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension" @default.
• W1964411946 cites W101090077 @default.
• W1964411946 cites W1514415492 @default.
• W1964411946 cites W1553503019 @default.
• W1964411946 cites W1554641506 @default.
• W1964411946 cites W1554881453 @default.
• W1964411946 cites W1654091726 @default.
• W1964411946 cites W1666404037 @default.
• W1964411946 cites W1749382062 @default.
• W1964411946 cites W174973653 @default.
• W1964411946 cites W179721640 @default.
• W1964411946 cites W181242617 @default.
• W1964411946 cites W1823399426 @default.
• W1964411946 cites W1823486301 @default.
• W1964411946 cites W1825548390 @default.
• W1964411946 cites W1901319567 @default.
• W1964411946 cites W1965247887 @default.
• W1964411946 cites W1966407346 @default.
• W1964411946 cites W1967198635 @default.
• W1964411946 cites W1968239929 @default.
• W1964411946 cites W1968959045 @default.
• W1964411946 cites W1970096689 @default.
• W1964411946 cites W1970491391 @default.
• W1964411946 cites W1970576963 @default.
• W1964411946 cites W1971420662 @default.
• W1964411946 cites W197303752 @default.
• W1964411946 cites W1973467450 @default.
• W1964411946 cites W1973476283 @default.
• W1964411946 cites W1974555120 @default.
• W1964411946 cites W1975347355 @default.
• W1964411946 cites W1975598811 @default.
• W1964411946 cites W1976256891 @default.
• W1964411946 cites W1976378426 @default.
• W1964411946 cites W1977538803 @default.
• W1964411946 cites W1977917959 @default.
• W1964411946 cites W1979526859 @default.
• W1964411946 cites W1979611691 @default.
• W1964411946 cites W1979917817 @default.
• W1964411946 cites W1980734258 @default.
• W1964411946 cites W1982820510 @default.
• W1964411946 cites W1983062597 @default.
• W1964411946 cites W1986010103 @default.
• W1964411946 cites W1989371535 @default.
• W1964411946 cites W1990693343 @default.
• W1964411946 cites W1991110995 @default.
• W1964411946 cites W1992666158 @default.
• W1964411946 cites W1993468667 @default.
• W1964411946 cites W1993845357 @default.
• W1964411946 cites W1994273426 @default.
• W1964411946 cites W1994279149 @default.
• W1964411946 cites W1996329002 @default.
• W1964411946 cites W1997448832 @default.
• W1964411946 cites W1998640491 @default.
• W1964411946 cites W2001137775 @default.
• W1964411946 cites W2001493083 @default.
• W1964411946 cites W2001650220 @default.
• W1964411946 cites W2002458428 @default.
• W1964411946 cites W2002696453 @default.
• W1964411946 cites W2003258814 @default.
• W1964411946 cites W2005092574 @default.
• W1964411946 cites W2005532868 @default.
• W1964411946 cites W2005771060 @default.
• W1964411946 cites W2007011015 @default.
• W1964411946 cites W2009371947 @default.
• W1964411946 cites W2010370984 @default.
• W1964411946 cites W2010954319 @default.
• W1964411946 cites W2011415923 @default.
• W1964411946 cites W2011457139 @default.
• W1964411946 cites W2016394659 @default.
• W1964411946 cites W2016598088 @default.
• W1964411946 cites W2018234166 @default.
• W1964411946 cites W2022619776 @default.
• W1964411946 cites W2022990509 @default.
• W1964411946 cites W2025400870 @default.
• W1964411946 cites W2025758893 @default.
• W1964411946 cites W2025800122 @default.
• W1964411946 cites W2026167796 @default.
• W1964411946 cites W2027392197 @default.
• W1964411946 cites W2028273955 @default.
• W1964411946 cites W2030930908 @default.
• W1964411946 cites W2031189373 @default.
• W1964411946 cites W2032703583 @default.
• W1964411946 cites W2034320774 @default.
• W1964411946 cites W2034456201 @default.
• W1964411946 cites W2035563144 @default.
• W1964411946 cites W2035635135 @default.
• W1964411946 cites W2036724960 @default.
• W1964411946 cites W2036943696 @default.
• W1964411946 cites W2037281102 @default.
• W1964411946 cites W2037621106 @default.
• W1964411946 cites W2041553454 @default.
• W1964411946 cites W2041714207 @default.
• W1964411946 cites W2041955799 @default.

• next